Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoGenex Pharmaceuticals, Inc. on November 8, 2010, reporting events occurring on November 5, 2010. The filing addresses the appointment of a new Chief Financial Officer and Executive Vice President of Operations. Note: The request metadata references "ACHIEVE LIFE SCIENCES, INC.", but the filing text explicitly identifies the registrant as OncoGenex Pharmaceuticals, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Appointment: Michelle Burris was appointed as Executive Vice President, Operations and Chief Financial Officer, effective January 3, 2011.
- Board Changes: Ms. Burris resigned from her Board committee positions but remains a director. David V. Smith succeeded her as Chair of the Audit Committee.
- Interim CFO Transition: Cameron Lawrence, who served as interim CFO, will step down from that role to continue as Director of Financial Reporting.
Compensation, Outlook, and Risks
Compensation Arrangements
- Base Salary: $365,000 annually.
- Discretionary Bonus: Up to 35% of base pay.
- Equity Grant: Stock option to purchase 35,000 shares of common stock under the 2010 Performance Incentive Plan.
- Termination Benefits (Involuntary): 12 months of base salary plus 30 days' salary if no notice is given; 12 months of COBRA premiums; accelerated vesting of equity that would have vested over 12 months.
- Change in Control Benefits: 15 months of base salary plus 12 months of average bonus earnings; 15 months of COBRA premiums; full acceleration of all equity vesting.
Risks and Covenants
The Employment Agreement includes non-solicitation and non-compete covenants for 12 months following termination, along with confidentiality and non-disparagement clauses. Termination benefits are contingent upon the execution of a general release of claims against the Company.
Investor Verification Checklist
- Verify the effective date of the new CFO appointment (January 3, 2011) and the interim status of the current financial leadership.
- Review the attached Press Release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Confirm the terms of the 2010 Performance Incentive Plan regarding the 35,000 share option grant.
- Assess the potential financial impact of the change-in-control provisions on future M&A scenarios.